Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT04198766 is registered in ClinicalTrials.gov with Inhibrx Biosciences, Inc as lead sponsor.

NCT NCT04198766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04198766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Inhibrx Biosciences, Inc
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 10, 2019
Completion date
July 31, 2033
Enrollment
340 (estimated)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, head and neck cancer, melanoma, non-small cell lung cancer, renal cell carcinoma, resectable non-small-cell lung cancer, solid tumor, urothelial carcinoma